Gossamer Bio Inc (GOSS NASDAQ) stock market data APIs
$0.4256
0.17(39.9%)
as of February 23, 2026
Try our APIs with
free plan!
Gossamer Bio Inc Financial Data Overview
Price chart is built with
Anychart
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Prev. Close
0.4256
Open
0.594
High
0.5941
Low
0.3327
52 wk Range
0.332-3.87
Market Cap
97 975 K
Shares Outstanding
231 M
Revenue
44 051 K
EPS
-0.21
Beta
1.947
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Gossamer Bio Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Gossamer Bio Inc data using free add-ons & libraries
Get Gossamer Bio Inc Fundamental Data
Gossamer Bio Inc Fundamental data includes:
- Net Revenue: 44 051 K
- EBITDA: -153 215 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: -0.19
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Gossamer Bio Inc News
New
Qualcomm, Booking Holdings upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...
BC-Most Active Stocks
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Tian Ruixiang Holdings Ltd. 506...
Analysts Remain Bullish on Gossamer Bio (GOSS) Citing Undervaluation
Gossamer Bio Inc. (NASDAQ:GOSS) is one of the best stocks under $3 to invest in. On February 4, H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Gossamer Bio and set a $10 price tar...
Mohammed Hadi Al-Rasheed And 2 Emerging Middle East Small Caps with Promising Potential
As the Middle East navigates a period of market volatility driven by fluctuating oil prices and geopolitical tensions, small-cap stocks in the region present unique opportunities for investors seeking...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
